@anapolitano_md provided latest updates on #angiosarcoma including @VaiaFlorou study @GreekSarc #Sarcoma https://t.co/ZbSdtSKDvK https://t.co/rldD14AXn0
RT @JTrentMDPhD: #Angiosarcoma patients treated with immune checkpoint inhibitors: At 12 weeks, 71% had partial response on imaging and/or…
RT @JTrentMDPhD: #Angiosarcoma patients treated with immune checkpoint inhibitors: At 12 weeks, 71% had partial response on imaging and/or…
#Angiosarcoma patients treated with immune checkpoint inhibitors: At 12 weeks, 71% had partial response on imaging and/or clinical exam and 29% had progressive disease. https://t.co/HdAGQYNbUR
RT @JTrentMDPhD: @wagsmd @Dr_R_Kurzrock @PatelOncology @SWOG @jitcancer @fredhutch @SeattleCCA Study by @wagsmd @fredhutch confirms efficac…
RT @BSB_Sandro: And the immune system can control angiosarcoma. That's a major step in a desert therapeutic landscape.
And the immune system can control angiosarcoma. That's a major step in a desert therapeutic landscape.
RT @Dr_R_Kurzrock: This initial study inspired our DART study to add angiosarcoma cohort. Kudos to you for getting the ball rolling. May…
RT @Dr_R_Kurzrock: This initial study inspired our DART study to add angiosarcoma cohort. Kudos to you for getting the ball rolling. May…
RT @JTrentMDPhD: @wagsmd @Dr_R_Kurzrock @PatelOncology @SWOG @jitcancer @fredhutch @SeattleCCA Study by @wagsmd @fredhutch confirms efficac…
RT @Dr_R_Kurzrock: This initial study inspired our DART study to add angiosarcoma cohort. Kudos to you for getting the ball rolling. May…
RT @Dr_R_Kurzrock: This initial study inspired our DART study to add angiosarcoma cohort. Kudos to you for getting the ball rolling. May…
RT @Dr_R_Kurzrock: This initial study inspired our DART study to add angiosarcoma cohort. Kudos to you for getting the ball rolling. May…
This initial study inspired our DART study to add angiosarcoma cohort. Kudos to you for getting the ball rolling. Maybe NCCN will incorporate into their guidelines.
RT @JTrentMDPhD: @wagsmd @Dr_R_Kurzrock @PatelOncology @SWOG @jitcancer @fredhutch @SeattleCCA Study by @wagsmd @fredhutch confirms efficac…
RT @JTrentMDPhD: @wagsmd @Dr_R_Kurzrock @PatelOncology @SWOG @jitcancer @fredhutch @SeattleCCA Study by @wagsmd @fredhutch confirms efficac…
RT @jbuell01: Yes! Early & pathbreaking findings by @breelynwilkyMD @VaiaFlorou @JTrentMDPhD in #angiosarcoma. Thrilled to see additiona…
RT @jbuell01: Yes! Early & pathbreaking findings by @breelynwilkyMD @VaiaFlorou @JTrentMDPhD in #angiosarcoma. Thrilled to see additiona…
RT @JTrentMDPhD: @wagsmd @Dr_R_Kurzrock @PatelOncology @SWOG @jitcancer @fredhutch @SeattleCCA Study by @wagsmd @fredhutch confirms efficac…
RT @jbuell01: Yes! Early & pathbreaking findings by @breelynwilkyMD @VaiaFlorou @JTrentMDPhD in #angiosarcoma. Thrilled to see additiona…
Yes! Early & pathbreaking findings by @breelynwilkyMD @VaiaFlorou @JTrentMDPhD in #angiosarcoma. Thrilled to see additional validation and benefit to patients @wagsmd @Dr_R_Kurzrock
RT @JTrentMDPhD: @wagsmd @Dr_R_Kurzrock @PatelOncology @SWOG @jitcancer @fredhutch @SeattleCCA Study by @wagsmd @fredhutch confirms efficac…
@wagsmd @Dr_R_Kurzrock @PatelOncology @SWOG @jitcancer @fredhutch @SeattleCCA Study by @wagsmd @fredhutch confirms efficacy of #immunotherapy for patient with #angiosarcoma #sarcoma @VaiaFlorou @breelynwilkyMD @drkomanduri @jbuell01 https://t.co/HdAGQYvB
@wagsmd @PestanaRC @Dr_R_Kurzrock @PatelOncology @SWOG @jitcancer @fredhutch @SeattleCCA Without doubt. There is a 71% response rate in #angiosarcoma patients treated with #immunotherapy checkpoint inhibitor @SylvesterCancer https://t.co/HdAGQYvB3j
RT @JTrentMDPhD: Dr. Wagner on the Rationale for Immunotherapy in #Angiosarcoma discussing our proof-of-principle study by @VaiaFlorou @…
RT @JTrentMDPhD: Dr. Wagner on the Rationale for Immunotherapy in #Angiosarcoma discussing our proof-of-principle study by @VaiaFlorou @…
RT @JTrentMDPhD: Dr. Wagner on the Rationale for Immunotherapy in #Angiosarcoma discussing our proof-of-principle study by @VaiaFlorou @…
Dr. Wagner on the Rationale for Immunotherapy in #Angiosarcoma discussing our proof-of-principle study by @VaiaFlorou @breelynwilkyMD @drkomanduri @jbuell01 https://t.co/HdAGQYNbUR https://t.co/3VHlkLAfIc
RT @JTrentMDPhD: @DrCeSarcoma For patients with #angiosarcoma we use chemotherapy initially with consideration of immune checkpoint inhibit…
RT @JTrentMDPhD: @DrCeSarcoma For patients with #angiosarcoma we use chemotherapy initially with consideration of immune checkpoint inhibit…
@DrCeSarcoma For patients with #angiosarcoma we use chemotherapy initially with consideration of immune checkpoint inhibitors. The role of surgery and reirradiation are discussed case by case at multidisciplinary #sarcoma conference . https://t.co/HdAGQYNb
RT @JTrentMDPhD: @Martin_AngelMD @fwaisberg1 @OncoAlert @SelnetH2020 @tomassoule @DrCeSarcoma Very exciting! Hazy lung met is typical in #A…
RT @JTrentMDPhD: @SprakerMDPhD @QuadShotNews @prg266 Congratulations! This is a great approach. Would like to see immune checkpoint inhibit…
RT @NGoelMD: I second that!
I second that!
@SprakerMDPhD @QuadShotNews @prg266 Congratulations! This is a great approach. Would like to see immune checkpoint inhibitor #Immunotherapy included in trials for cutaneous #angiosarcoma. https://t.co/HdAGQYvB3j
@CureSarcoma Thank you @CureSarcoma for raising Angiosarcoma awareness. It’s difficult to diagnose and challenging to treat. >70% of pts w #angiosarcoma whose cancer grew on chemotherapy had tumor regression with immunotherapy @SylvesterCancer. Clinical
@TNradonc @evicorehc Challenging situation. As an option, heavily pretreated Angiosarcoma patients had a 71% response rate to immune checkpoint inhibitors in our series @SylvesterCancer https://t.co/HdAGQYvB3j
RT @jbuell01: Impressive data @SylvesterCancer furthering the pioneering #sarcoma findings https://t.co/LoHeTERBrf by @VaiaFlorou @breely…
RT @jbuell01: Impressive data @SylvesterCancer furthering the pioneering #sarcoma findings https://t.co/LoHeTERBrf by @VaiaFlorou @breely…
Impressive data @SylvesterCancer furthering the pioneering #sarcoma findings https://t.co/LoHeTERBrf by @VaiaFlorou @breelynwilkyMD @JTrentMDPhD
@NamBuiMD @KristenGanjoo Great data. Congratulations. Which #sarcoma histology had the Complete Response? We’ve only seen CR with cutaneous #angiosarcoma. @jitcancer https://t.co/VaIiK0SKN6
@RZitwer @JMGardnerMD @KMirza @Sara_Jiang @SGottesmanMD @histiocytosisX @smlungpathguy @TristanRutland7 @KBaranoma @AadilAhmedMD @KCampbellMD @MightyDermPath We rely heavily on #sarcoma pathology expertise. Critical to recognize cutaneous #angiosarcoma. &g
@NamBuiMD Immune checkpoint inhibitors are exceptionally effective against cutaneous angiosarcoma. https://t.co/VaIiK0SKN6
RT @JTrentMDPhD: @Martin_AngelMD @fwaisberg1 @OncoAlert @SelnetH2020 @tomassoule @DrCeSarcoma Very exciting! Hazy lung met is typical in #A…
RT @JTrentMDPhD: @Martin_AngelMD @fwaisberg1 @OncoAlert @SelnetH2020 @tomassoule @DrCeSarcoma Very exciting! Hazy lung met is typical in #A…
RT @JTrentMDPhD: @Martin_AngelMD @fwaisberg1 @OncoAlert @SelnetH2020 @tomassoule @DrCeSarcoma Very exciting! Hazy lung met is typical in #A…
@Martin_AngelMD @fwaisberg1 @OncoAlert @SelnetH2020 @tomassoule @DrCeSarcoma Very exciting! Hazy lung met is typical in #Angiosarcoma. We found cutaneous and XRT-associated AS pts have >70% RR to ICIs https://t.co/udX3EneuK2 @SylvesterCancer @GinaDAmato
RT @JTrentMDPhD: @Dr_R_Kurzrock Agree, we’ve seen impressive results of #Immunotherapy ICI in cutaneous #Angiosarcoma: At 12 weeks 71% of p…
@Dr_R_Kurzrock Agree, we’ve seen impressive results of #Immunotherapy ICI in cutaneous #Angiosarcoma: At 12 weeks 71% of patients had a partial response of their lesions. @SylvesterCancer @jitcancer https://t.co/udX3EneuK2
RT @JTrentMDPhD: @histiocytosisX @herbloong #Angiosarcoma is challenging to diagnose and manage but new treatments are on the horizon: @Vai…
@histiocytosisX @herbloong #Angiosarcoma is challenging to diagnose and manage but new treatments are on the horizon: @VaiaFlorou @NGoelMD @wilky @AndreaEspejoMD Andrew Rosenberg @SylvesterCancer https://t.co/udX3EneuK2
RT @jitcancer: On #RareDiseaseDay we highlight the potential for #immunotherapy in #angiosarcoma & #sarcoma. Great work @breelynwilkyMD @JT…
RT @JTrentMDPhD: First series to show #immunotherapy is effective in cutaneous #angiosarcoma #sarcoma. Great study with @VaiaFlorou and @br…
RT @jitcancer: On #RareDiseaseDay we highlight the potential for #immunotherapy in #angiosarcoma & #sarcoma. Great work @breelynwilkyMD @JT…
RT @JTrentMDPhD: First series to show #immunotherapy is effective in cutaneous #angiosarcoma #sarcoma. Great study with @VaiaFlorou and @br…
RT @jitcancer: On #RareDiseaseDay we highlight the potential for #immunotherapy in #angiosarcoma & #sarcoma. Great work @breelynwilkyMD @JT…
@VaiaFlorou congratulations! @jitcancer @sitcancer
RT @jitcancer: On #RareDiseaseDay we highlight the potential for #immunotherapy in #angiosarcoma & #sarcoma. Great work @breelynwilkyMD @JT…
First series to show #immunotherapy is effective in cutaneous #angiosarcoma #sarcoma. Great study with @VaiaFlorou and @breelynwilkyMD @SylvesterCancer in @jitcancer
RT @jitcancer: On #RareDiseaseDay we highlight the potential for #immunotherapy in #angiosarcoma & #sarcoma. Great work @breelynwilkyMD @JT…
RT @jitcancer: On #RareDiseaseDay we highlight the potential for #immunotherapy in #angiosarcoma & #sarcoma. Great work @breelynwilkyMD @JT…
On #RareDiseaseDay we highlight the potential for #immunotherapy in #angiosarcoma & #sarcoma. Great work @breelynwilkyMD @JTrentMDPhD & @ALLIANCE_org A091401 by @sandrapdangelo @bvantine1! Keep up the momentum! @CureSarcoma @SARCtrials @DrSarcoma
RT @JTrentMDPhD: A Herculean effort to better understand #angiosarcoma. Delighted to see our series of cutaneous #angiosarcoma patients tre…
RT @JTrentMDPhD: Our second publication in 3 months documenting exceptional efficacy of #immunotherapy in the treatment of #Sarcoma patient…
RT @JTrentMDPhD: A Herculean effort to better understand #angiosarcoma. Delighted to see our series of cutaneous #angiosarcoma patients tre…
RT @JTrentMDPhD: A Herculean effort to better understand #angiosarcoma. Delighted to see our series of cutaneous #angiosarcoma patients tre…
RT @JTrentMDPhD: A Herculean effort to better understand #angiosarcoma. Delighted to see our series of cutaneous #angiosarcoma patients tre…
RT @JTrentMDPhD: A Herculean effort to better understand #angiosarcoma. Delighted to see our series of cutaneous #angiosarcoma patients tre…
RT @JTrentMDPhD: A Herculean effort to better understand #angiosarcoma. Delighted to see our series of cutaneous #angiosarcoma patients tre…
A Herculean effort to better understand #angiosarcoma. Delighted to see our series of cutaneous #angiosarcoma patients treated with immune checkpoint inhibitors validated. https://t.co/udX3Enw5BA @jitcancer @SylvesterCancer https://t.co/z22egnJcfr
RT @JTrentMDPhD: @SylvesterCancer study of #immunotherapy for #angiosarcoma patients highlighted @myESMO. Impressive 71% objective response…
RT @JTrentMDPhD: @SylvesterCancer study of #immunotherapy for #angiosarcoma patients highlighted @myESMO. Impressive 71% objective response…
@SylvesterCancer study of #immunotherapy for #angiosarcoma patients highlighted @myESMO. Impressive 71% objective response rate. https://t.co/udX3EneuK2 https://t.co/tD7dW2EshA
RT @sandrapdangelo: Valuable case series highlighting role of immune checkpoint inhibitors in #angiosarcoma! https://t.co/N5JQNDgjAa
RT @sitcancer: #JITC Case Report: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a s…
RT @sitcancer: #JITC Case Report: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a s…
#JITC Case Report: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution https://t.co/aVbYjzmuV9
#JITC Case Report: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution https://t.co/aVbYjzmuV9
RT @JTrentMDPhD: New treatment option for #Angiosarcoma patients: immune checkpoint inhibitors @OncoAlert @SylvesterCancer #immunothera…
RT @JTrentMDPhD: New treatment option for #Angiosarcoma patients: immune checkpoint inhibitors @OncoAlert @SylvesterCancer #immunothera…
RT @JTrentMDPhD: New treatment option for #Angiosarcoma patients: immune checkpoint inhibitors @OncoAlert @SylvesterCancer #immunothera…
RT @JTrentMDPhD: New treatment option for #Angiosarcoma patients: immune checkpoint inhibitors @OncoAlert @SylvesterCancer #immunothera…
RT @JTrentMDPhD: New treatment option for #Angiosarcoma patients: immune checkpoint inhibitors @OncoAlert @SylvesterCancer #immunothera…
RT @JTrentMDPhD: New treatment option for #Angiosarcoma patients: immune checkpoint inhibitors @OncoAlert @SylvesterCancer #immunothera…
New treatment option for #Angiosarcoma patients: immune checkpoint inhibitors @OncoAlert @SylvesterCancer #immunotherapy https://t.co/6fNda84bDJ
RT @JTrentMDPhD: Our second publication in 3 months documenting exceptional efficacy of #immunotherapy in the treatment of #Sarcoma patient…
RT @sitcancer: #JITC Case Report: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a s…
#JITC Case Report: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution https://t.co/aVbYjzE6jJ
Reading "Angiosarcoma patients treated with immune checkpoint inhibitors" (https://t.co/S5LQrcDeE2) by @breelynwilkyMD, Remarkable how once in a while aCTLA-4 is effectively curative, in this case at a low dose (0.1mg/kg). Curious: decreasing NK cells
RT @drkomanduri: Happy to collaborate with my incredibly talented #sarcoma colleagues @breelynwilkyMD @VaiaFlorou @JTrentMDPhD in helping t…
RT @sandrapdangelo: Valuable case series highlighting role of immune checkpoint inhibitors in #angiosarcoma! https://t.co/N5JQNDgjAa